Screener
Summit Therapeutics SMMT Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Oncology clinical trial related costs | $90,195 | $36,363 |
| Compensation related costs, excluding stock-based compensation | 26,432 | 15,854 |
| Stock-based compensation | 72,791 | 11,096 |
| Other expenses (1) | 5,794 | 3,538 |
| Total segment expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's business segments — R&D?
- Summit Therapeutics (SMMT) reported business segments — R&D of $90.2M in Q1 2026.
- How has Summit Therapeutics's business segments — R&D changed year-over-year?
- Summit Therapeutics's business segments — R&D increased by 148.0% year-over-year, from $36.36M to $90.2M.
- What does business segments — R&D mean?
- Represents the costs incurred by the business segment for internal research and development activities aimed at discovering and developing new pharmaceutical products. This includes clinical trial expenses, laboratory research, and regulatory filing costs necessary to bring drug candidates to market.
Ask your AI about Summit Therapeutics's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude